OAM
ALDR

Oxford Asset Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Oxford Asset Management’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-100,864
Closed -$3.31M – 923
2016
Q3 		$3.31M Buy
+100,864
New +$3.07M 0.1% 263

Other funds holding ALDR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Oxford Asset Management's ALDR Position: Q4 2016 in Review

Oxford Asset Management sold out of Alder Biopharmaceuticals (ALDR) in Q4 2016, closing a stake of 100,864 shares — an estimated $3.31M sold.

Oxford Asset Management first reported a position in ALDR in Q3 2016 and held it in 1 quarter. The position peaked at $3.31M in Q3 2016. 145 funds tracked by Wall St. Rank hold ALDR as of Q4 2016.

  • Oxford Asset Management reported no remaining Alder Biopharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Oxford Asset Management sold 100,864 Alder Biopharmaceuticals shares in Q4 2016, an estimated $3.31M.
  • Oxford Asset Management first reported a position in Alder Biopharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Oxford Asset Management's Alder Biopharmaceuticals position peaked at $3.31M in Q3 2016.
  • 145 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2016.

Based on Oxford Asset Management's 13F filing for Q4 2016, filed 9 Feb 2017.